Published in Cancer Chemother Pharmacol on January 01, 1998
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics (2013) 1.30
Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol (2013) 1.11
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat (2009) 1.08
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer (2010) 1.05
CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature (2015) 0.99
Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol (2011) 0.96
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol (2007) 0.96
Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy. Neoplasia (2013) 0.84
DNA demethylating antineoplastic strategies: a comparative point of view. Genes Cancer (2010) 0.83
Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev (2015) 0.83
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia. Exp Hematol Oncol (2013) 0.81
Human cytidine deaminase: a biochemical characterization of its naturally occurring variants. Int J Biol Macromol (2013) 0.80
Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs (2013) 0.78
Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One (2012) 0.75
Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines. Pharmacol Res Perspect (2016) 0.75
Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells. Protein Eng Des Sel (2016) 0.75
Partial purification and properties of two forms of deoxyribonucleic acid polymerase from calf thymus. J Biol Chem (1973) 2.31
Effect of cytosine arabinoside 5'-triphosphate on mammalian DNA polymerase. Biochem Biophys Res Commun (1969) 2.16
Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen. Mol Cell Biol (1987) 1.99
Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res (1976) 1.70
A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Cancer Res (1974) 1.48
Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol (1983) 1.37
Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol (1983) 1.24
Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res (1983) 1.19
Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis (2005) 1.19
Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol (1993) 1.15
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res (1981) 1.15
Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res (1989) 1.08
Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther (1985) 1.08
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol (1992) 1.07
Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther (1985) 1.07
Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem (1968) 1.06
Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res (1984) 1.04
In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. Cancer Res (1977) 1.04
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol (2001) 1.03
Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. Cancer Res (1983) 1.03
Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol (1972) 1.03
DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs (1999) 1.01
Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta (1968) 1.01
Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs (1998) 1.00
Mammalian deoxynucleoside kinases. II. Deoxyadenosine kinase: purification and properties. J Biol Chem (1971) 0.99
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leuk Res (1985) 0.97
Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase. Biochem Pharmacol (1979) 0.97
Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol (1984) 0.95
High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. J Pharm Sci (1981) 0.94
Characterization of recombinant helper retroviruses from Moloney-based vectors in ecotropic and amphotropic packaging cell lines. Virology (1991) 0.93
Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res (1994) 0.90
Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts. Nucleic Acids Res (1999) 0.89
Hemolytic anemia following intravenous gamma globulin administration. Am J Med (1987) 0.87
Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs (1997) 0.86
Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res (1974) 0.85
Sample preparation for the determination of 5-aza-2'-deoxycytidine in plasma by high-performance liquid chromatography. J Chromatogr (1985) 0.83
Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. Leuk Res (1986) 0.83
Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia. Cancer Treat Rep (1984) 0.83
Studies on the phosphorylation of cytosine arabinoside in mammalian cells. Mol Pharmacol (1971) 0.83
Effect of DNA polymerase on nuclei from different phases of cell cycle. Eur J Biochem (1974) 0.82
Mammalian deoxynucleoside kinases. IV. Deoxythymidine kinase: purification, properties, and kinetic studies. J Biol Chem (1971) 0.81
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther (2001) 0.81
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res (1995) 0.81
Mammalian deoxynucleoside kinases. 3. Deoxyadenosine kinase: inhibition by nucleotides and kinetic studies. J Biol Chem (1971) 0.81
Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J Viral Hepat (2006) 0.80
5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk Res (1984) 0.80
Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells. Leuk Res (1993) 0.80
Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs (1991) 0.80
Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. Cancer Res (1994) 0.80
Toxicology in mice of the antileukemic agent 5-aza-2'-deoxycytidine. Drug Chem Toxicol (1981) 0.80
Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Ther (1997) 0.80
Increased sensitivity to a vitamin D3 analog in HL-60 myeloid leukemic cells resistant to all-trans retinoic acid. Leukemia (1994) 0.79
Inhibition of cytotoxic action of 1- -D-arabinofuranosylcytosine on S-phase HeLa cells by 5-fluorodeoxyuridine. Cancer Res (1973) 0.79
Effect of tRNA from 5-azacytidine-treated hamster fibrosarcoma cells on protein synthesis in vitro in a cell-free system. Biochem Pharmacol (1976) 0.79
Kinetic studies with 5-azacytidine-5'-triphosphate and DNA-dependent RNA polymerase. Biochem Pharmacol (1977) 0.79
Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase. Mol Pharmacol (1984) 0.79
The regulatory properties of deoxyadenosine kinase. Biochim Biophys Acta (1968) 0.79
Enzymatic estimation and metabolism of 1- -D-arabinofuranosylcytosine in man. Cancer Res (1972) 0.78
Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells. Cancer Treat Rep (1984) 0.78
In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination. Cancer Res (1975) 0.78
Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. Gene Ther (2002) 0.78
Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells. Cancer Res (1979) 0.78
In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine. Semin Oncol (1987) 0.78
Retroviral transfer and long-term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice. Gene Ther (1998) 0.78
Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. Leuk Res (1996) 0.78
Genetic analysis of the yeast NUD1 endo-exonuclease: a role in the repair of DNA double-strand breaks. Curr Genet (1998) 0.77
Effect of 5-aza-2'-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells. Cancer Chemother Pharmacol (1998) 0.77
Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate. Hum Gene Ther (1998) 0.77
Enzymatic synthesis of 5-azacytidine 5'-triphosphate from 5-azacytidine. Anal Biochem (1976) 0.77
Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts. Cancer Gene Ther (2000) 0.77
Gene therapy: here to stay. CMAJ (1995) 0.77
Quantitation of inhibition of DNA methylation of the retinoic acid receptor beta gene by 5-Aza-2'-deoxycytidine in tumor cells using a single-nucleotide primer extension assay. Anal Biochem (2000) 0.77
Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. Anticancer Drugs (1996) 0.77
Transient expression of Saccharomyces cerevisiae endo-exonuclease NUD1 gene increases the frequency of extrachromosomal homologous recombination in mouse Ltk- fibroblasts. Mutat Res (1999) 0.76
Enhancement of the antileukemic activity of 5-aza-2'-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells. Anticancer Drugs (1994) 0.76
The effect of the Saccharomyces cerevisiae endo-exonuclease NUD1 gene expression on the resistance of HeLa cells to DNA-damaging agents. Mutat Res (1999) 0.76
5-Aza-2'-deoxycytidine as inducer of differentiation and growth inhibition in mouse neuroblastoma cells. Cell Differ Dev (1989) 0.76
Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion (1993) 0.76
Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Anticancer Drugs (1993) 0.76
Biochemical pharmacology of cytosine arabinoside. Med Pediatr Oncol (1982) 0.76
Gene transfer into humans: a first step. N Engl J Med (1990) 0.75
Drug sensitivity test for patients with acute leukemia on high-dose ara-C therapy. Semin Oncol (1985) 0.75
Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography. Ther Drug Monit (1983) 0.75
Potential of ribozymes against deoxycytidine kinase to confer drug resistance to cytosine nucleoside analogs. Biochem Biophys Res Commun (2000) 0.75
Studies on analogs of isosteric and allosteric ligands of deoxycytidylate aminohydrolase. Biochemistry (1970) 0.75
Effects of trimethoprim on leukaemic cells in vitro. Br J Haematol (1981) 0.75
Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene. Prog Exp Tumor Res (1999) 0.75
Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Hum Gene Ther (1996) 0.75
5-AZA-2'-deoxycytidine synergistic action with thymidine on leukemic cells and interaction of 5-AZA-dCMP with dCMP deaminase. Adv Exp Med Biol (1986) 0.75
[In vitro test for studying sensitivity to Ara-C in leukemic patients]. Union Med Can (1987) 0.75
Gene amplification of human cytidine deaminase proviral cDNA and increased levels of its mRNA produces enhanced drug resistance to cytosine arabinoside in retroviral-transduced murine fibroblasts. Cancer Lett (1999) 0.75
Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine. Int J Cancer (1982) 0.75
Trisomy 9 in hematologic disorders: possible association with primary thrombocytosis. Cancer Genet Cytogenet (1987) 0.75
Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells. Anticancer Drugs (1992) 0.75
Relationship of nutritional factors to in vitro tumor cell growth and cytotoxicity produced by cytosine arabinoside. Cell Tissue Kinet (1977) 0.75